Cargando…
Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
BACKGROUND: Peginterferon beta-1a administered every 2 weeks via subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated injection site reactions (ISRs) can lead to treatme...
Autores principales: | Zhao, Yuan, Chen, Kun, Ramia, Nancy, Sahu, Sangeeta, Kumar, Achint, Naylor, Maria L., Zhu, Li, Naik, Himanshu, Butts, Cherié L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883310/ https://www.ncbi.nlm.nih.gov/pubmed/33628334 http://dx.doi.org/10.1177/1756286420975227 |
Ejemplares similares
-
Levocetirizine Oral Disintegrating Tablet: A Randomized Open‐Label Crossover Bioequivalence Study in Healthy Japanese Volunteers
por: Ino, Hiroko, et al.
Publicado: (2020) -
COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016) -
Bioequivalence of a biosimilar enoxaparin sodium to Clexane(®) after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers
por: Martínez González, Javier, et al.
Publicado: (2018) -
Evaluation of pharmacokinetics and safety with bioequivalence of Amlodipine in healthy Chinese volunteers: Bioequivalence Study Findings
por: Wang, Tongtong, et al.
Publicado: (2020) -
Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach
por: White, Sarah, et al.
Publicado: (2021)